Search

Objective: Metabolic syndrome is a health-threatening condition suffered by approximately one third of schizophrenia patients and largely attributed to antipsychotic medication. Previous evidence reports a common genetic background of psychotic and metabolic disorders. In this study, we aimed to assess the role of polygenic risk scores (PRSs) on the progression of the metabolic profile in a first-episode psychosis (FEP) cohort. Method: Of the 231 FEP individuals included in the study, 192–220 participants were included in basal analysis and 118–179 in longitudinal 6-month models. Eleven psychopathologic and metabolic PRSs were constructed. Basal and longitudinal PRSs association with metabolic measurements was assessed by statistical analyses. Results: No major association of psychopathological PRSs with the metabolic progression was found. However, high risk individuals for depression and cholesterol-related PRSs reported a higher increase of cholesterol levels during the follow-up (FDR = 0.023 for all analyses). Their effect was comparable to other well-established pharmacological and environmental risk factors (explaining at least 1.2% of total variance). Conclusion: Our findings provide new evidence of the effects of metabolic genetic risk on the development of metabolic dysregulation. The future establishment of genetic profiling tools in clinical procedures could enable practitioners to better personalize antipsychotic treatment selection and dosage. © 2022

Supplemental material, Table_S1 for Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period by Patricia Gassó, Joan Albert Arnaiz, Sergi Mas, Amalia Lafuente, Miquel Bioque, Manuel J Cuesta, Covadonga M Díaz-Caneja, Clemente García, Antonio Lobo, Ana González-Pinto, Mara Parellada, Iluminada Corripio, Eduard Vieta, Josefina Castro-Fornieles, Anna Mané, Natalia Rodríguez, Daniel Boloc, Jerónimo Saiz-Ruiz and Miguel Bernardo in Journal of Psychopharmacology

Supplemental material, jop-2017-3257-File006 for Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis by Patricia Gassó, Sergi Mas, Miquel Bioque, Bibiana Cabrera, Antonio Lobo, Ana González-Pinto, Covadonga M. Díaz-Caneja, Iluminada Corripio, Eduard Vieta, Josefina Castro-Fornieles, Salvador Sarró, Anna Mané, Julio Sanjuan, Adrián Llerena, Amalia Lafuente, Jerónimo Saiz-Ruiz, Miguel Bernardo and PEPs Group in Journal of Psychopharmacology

Supplemental material, jop-2017-3257-File005 for Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis by Patricia Gassó, Sergi Mas, Miquel Bioque, Bibiana Cabrera, Antonio Lobo, Ana González-Pinto, Covadonga M. Díaz-Caneja, Iluminada Corripio, Eduard Vieta, Josefina Castro-Fornieles, Salvador Sarró, Anna Mané, Julio Sanjuan, Adrián Llerena, Amalia Lafuente, Jerónimo Saiz-Ruiz, Miguel Bernardo and PEPs Group in Journal of Psychopharmacology

Cytokine secretion by purified monocytes of early-onset OCD and healthy controls. (DOCX 24 kb)

Analysis of the percentages of total monocytes, monocyte subpopulations, and cytokine levels after LPS stimulation of purified monocytes in early-onset OCD diagnosed with different comorbidities. (DOCX 22 kb)

Gating strategy for identification of monocyte subpopulations. (DOCX 324 kb)

Correlations of the duration of disease (expressed in months) and symptom severity (assessed by CY-BOCS score), with the percentage of total monocytes, monocyte subpopulations, and cytokine levels after LPS stimulation of monocytes in early-onset OCD. (DOCX 13 kb)

Correlations between the five proinflammatory cytokines measured in the study in basal conditions and after LPS or LPS-dexamethasone stimulation. (DOCX 21 kb)

We investigated the relationship between several functional polymorphisms in genes coding for dopamine metabolism and transport enzymes (MAO-A VNTR; MAO-A 941T>G; DAT VNTR; DAT -67A/T; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*6) and the frequency of schizophrenia. Participants in the study were 242 subjects diagnosed with schizophrenia and related disorders and 290 hospital-based controls. Genomic DNA was isolated from whole blood and genotyped by several methods. However, there was no association between schizophrenia and the alleles, genotypes or diplotypes that were studied or their interactions. Polymorphisms in genes coding for dopamine metabolism and transport enzymes did not predispose to or protect from schizophrenia and related disorders. © 2009 The Authors Fundamental and Clinical Pharmacology © 2009 Société Française de Pharmacologie et de Thérapeutique.